<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351845</url>
  </required_header>
  <id_info>
    <org_study_id>203470</org_study_id>
    <nct_id>NCT00351845</nct_id>
  </id_info>
  <brief_title>Clinical Study to Test the Effects of a Low-Carbohydrate Diet on Body Weight</brief_title>
  <official_title>A Clinical Study to Evaluate the Effect of a Modified Carbohydrate Diet on Body Weight in Overweight or Obese Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provident Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provident Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of a modified carbohydrate diet versus a
      portion controlled diet in overweight or obese men and women on body weight.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences between and within modified carbohydrate and portion-controlled (control) diet treatment groups in the change from baseline (week 0) to week 12 and week 36 in body weight.</measure>
    <time_frame>week 12 and week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences between and within modified carbohydrate and control diet treatment groups in the change from baseline (week 0) to week 12 and week 36 in body fat mass (FM).</measure>
    <time_frame>wwek 12 and week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between and within modified carbohydrate and control diet treatment groups in the change from baseline (week 0) to week 12 and week 36 in trunk fat.</measure>
    <time_frame>week 12 and week 36</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low carbohydrate diet (behavior)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 to 65 years of age.

          -  Waist circumference measurement at Visit 1 (week -1) of ³ 87 cm for females and ³ 90
             cm for males.

          -  Subject agrees to discontinue all use of supplements or multivitamins (except for
             those provided during study period) by Visit 2 (week 0).

          -  Normally active and judged to be in good health on the basis of medical history and
             routine laboratory tests.

          -  Subject must be willing to follow the assigned diet and maintain usual physical
             activity level throughout the trial.

          -  Subject understands the procedures and requirements of the study by providing written
             informed consent and authorization for protected health information disclosure.

        Exclusion Criteria:

          -  Weight loss of &gt; 10 lb in the two months prior to screening.

          -  Body mass index (BMI) &gt; 37.0 kg/m2.

          -  Current smoker (any cigarette use) or history of smoking within 6 months prior to
             screening.

          -  Postmenopausal women who are current users of hormone therapy or have discontinued
             hormone therapy within 2 months prior to screening.

          -  History or presence of significant cardiac, renal, hepatic, pulmonary, biliary, or
             endocrine disorders.

          -  Uncontrolled hypertension (systolic blood pressure ³ 160 mm Hg or diastolic blood
             pressure ³ 100 mm Hg on two consecutive visits).

          -  History of recurrent nephrolithiasis, or an acute episode of nephrolithiasis within
             the last year prior to screening.

          -  History of symptomatic cholelithiasis, unless subject has undergone cholecystectomy.

          -  History of gastrointestinal surgery for weight-reducing purposes.

          -  Active gastrointestinal disorders such as peptic ulcer disease or malabsorption
             syndromes (controlled lactose intolerance or gastroesophageal reflux disease are
             acceptable.)

          -  Pancreatic disease: pancreatic enzyme deficiency, history of pancreatitis.

          -  Fasting blood glucose ≥ 126 mg/dL at visit 1 or diagnosed diabetes mellitus.

          -  Use of any weight loss medications, supplements, programs, or meal replacement
             products intended to alter body weight within 4 weeks of the screening visit or during
             the course of the study. Occasional use of meal replacement bars or shakes as snacks
             is acceptable.

          -  History or presence of cancer in the past 2 years, except for successfully resected
             basal cell carcinoma of the skin.

          -  Psychiatric disorders requiring medications (i.e., selective serotonin reuptake
             inhibitors) or which could interfere with the subject's compliance to the requirements
             of the protocol.

          -  History or current presence of any diagnosed eating disorders (binge eating, bulimia,
             history of anorexia).

          -  Use of systemic corticosteroids, androgens, or phenytoin.

          -  Use of pseudo-ephedrine during the study period.

          -  Use of lipid-lowering drugs or supplements, unless dose stable prior to enrollment (2
             months prior for drugs, 2 weeks prior for supplements).

          -  Use of drugs for regulating hemostasis, other than stable dose aspirin.

          -  Use of thyroid hormones, except stable-dose replacement therapy for ≥ 2 months prior
             to enrollment.

          -  Abnormal laboratory test results of clinical significance, including, but not limited
             to total cholesterol &gt; 300 mg/dL or triglycerides &gt; 400 mg/dL.

          -  Females who are pregnant, planning to be pregnant during the study period, lactating,
             or women of childbearing potential who are not using an approved method of
             contraception. A woman is considered to be of childbearing potential unless she is
             post-hysterectomy, post-tubal ligation, or ³ 1 year postmenopausal.

          -  Recent history of (within past 12 months) or strong potential for alcohol or substance
             abuse. Alcohol abuse will be defined as &gt; 14 drinks per week (1 drink = 12 oz beer, 4
             oz wine, or 1 ½ oz distilled spirits).

          -  Participation in another clinical study within 30 days prior to screening visit (week
             -1).

          -  Individual has a condition the Investigator believes would interfere with the
             evaluation of the subject or put the subject at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin C Maki, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research Chicago</affiliation>
  </overall_official>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2006</study_first_posted>
  <last_update_submitted>April 21, 2009</last_update_submitted>
  <last_update_submitted_qc>April 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kevin C. Maki, PhD</name_title>
    <organization>Provident Clinical Research</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

